MYGN · XBRL financial data

Myriad Genetics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MYGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	557	691	678	753	838	825
Cost of goods and services sold	—	—	202	236	252	248
Gross profit	—	—	476	517	585	577
Research and development	73	82	85	89	113	107
Selling, general and administrative	497	538	515	573	—	—
General and administrative	—	—	248	284	276	257
Total operating expenses	—	—	617	774	709	964
Operating income (loss)	(290)	(191)	(141)	(257)	(124)	(387)
Interest income	2	1	3	3	2	2
Interest expense	11	7	3	3	3	11
Other income (expense)	15	139	1	(4)	1	1
Income tax expense (benefit)	(60)	(30)	(29)	1	4	(29)
Net income (loss)	(224)	(27)	(112)	(263)	(127)	(366)
Earnings per share, basic USD per share	(2.99)	(0.35)	(1.39)	(3.18)	(1.41)	(3.95)
Earnings per share, diluted USD per share	(2.99)	(0.35)	(1.39)	(3.18)	(1.41)	(3.95)
Weighted average shares, basic millions of shares	75	78	81	83	91	93
Weighted average shares, diluted millions of shares	75	78	81	83	91	93

Fiscal years (MYGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	117	258	57	132	102	150
Marketable securities	34	81	58	9	0	—
Marketable securities, non-current	21	59	55	0	—	—
Accounts receivable	90	91	102	114	121	115
Inventory	27	15	20	22	28	31
Prepaid and other current assets	14	20	20	19	31	25
Total current assets	389	485	275	314	298	333
Property and equipment, net	41	44	83	119	117	114
Right-of-use asset	60	82	104	62	55	49
Goodwill	329	239	287	287	286	52
Total assets	1,419	1,321	1,199	1,147	1,028	707
Accounts payable	21	30	29	26	32	30
Accrued liabilities	79	157	94	114	119	97
Current portion of long-term debt	0	—	—	—	0	—
Total current liabilities	146	204	137	156	164	134
Long-term debt	225	0	0	39	40	120
Lease liability, non-current	51	79	131	97	88	83
Total liabilities	538	353	313	363	327	339
Accumulated deficit	(227)	(254)	(366)	(630)	(757)	(1,123)
Total stockholders' equity	881	968	886	783	701	368
Total liabilities and equity	1,419	1,321	1,199	1,147	1,028	707
Common shares outstanding (cover page) millions of shares	76	80	81	90	91	94

Fiscal years (MYGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(224)	(27)	(112)	(263)	(127)	(366)
Stock-based compensation	—	36	38	41	50	35
Net cash from operating activities	—	18	(106)	(111)	(9)	2
Net cash from investing activities	—	274	(78)	32	(12)	(27)
Share repurchases	—	0	—	—	—	—
Net cash from financing activities	—	(151)	(8)	153	(7)	64
Net change in cash	—	141	(192)	75	(29)	39

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Arbutus Biopharma	19	1	(6)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88	0.5	(10)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
aTYR PHARMA	16	not reported	(9.4)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Iovance Biotherapeutics	58	121	not reported	462.7M	—	Q3 FY26 10-QSep 30, 2026
Zevra Therapeutics	122	38	10*	59.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.